# webinars

ESH WEBINARS
2021

ESH WEBINARS 2021 on

Controversial and missing issues of recent hypertension guidelines

Hypertension is the major preventable cause of cardiovascular disease and all-cause death worldwide. It affects about 30-45% of adult population and becomes progressively more common with advancing age.
In fact, high blood pressure is responsible every year for about 10 million deaths and 200 million disability-adjusted life years globally. Strong evidence exists that lowering blood pressure in hypertension reduces associated morbidity and mortality. Unfortunately, blood pressure control rates and related risk reduction still remain poor worldwide.

A number of guidelines for the management of hypertension have been issued in recent years by several scientific societies. Guidelines evaluate and summarize published scientific evidence in order to assist doctors in applying the most appropriate management strategies for hypertensive patients. However, for a consistent number of topics there is still a low level of evidence, since many important questions related to diagnosis and treatment of hypertension have not been addressed so far by randomized clinical trials. Hence, controversial indications and missing issues still exist and should be properly analysed and discussed on the basis of the most recent clinical research studies.
Therefore, the European Society of Hypertension (ESH), which has published the 2018 Guidelines for the management of arterial hypertension together with the European Society of Cardiology, will organize two webinars on ‘Controversial and missing issues of recent hypertension guidelines’ with special focus on the following topics:

• Need for a more precise diagnosis of hypertension and of the associated risk with optimal use of out of office blood pressure measurement devices

• How to proceed for accurate diagnosis of secondary forms of hypertension

• Most effective treatment of hypertension, focusing on updated thresholds and targets of therapy, adherence to therapeutical prescription, best combination of drugs in different subgroups of patients, new possible indications for device based therapy

• Assessment and management of total cardiovascular risk in hypertensive patients, with an update on the use of new drugs effective for the control of associated risk factors and clinical complications

• Antihypertensive treatment during the still ongoing dramatic Covid-19 pandemic

The webinars will be made possible with an unconditioned support by Menarini Group and the technical organization of AIM Group International.

Prepare yourself, stay connected, enjoy the live and make the most of it!

Scientific Coordinator
Prof. E. Agabiti Rosei

#

FACULTY

Faculty

Enrico Agabiti-Rosei

Michel Burnier

Antonio Coca

Guido Grassi

Andrzej Januszewicz

Reinhold Kreutz

Giuseppe Mancia

Athanasios J. Manolis

Jose Redón Mas

Costas Tsioufis

-

ESH WEBINARS 2021

webinars

PART I

CONTROVERSIAL
AND MISSING ISSUES
OF RECENT HYPERTENSION
GUIDELINES

April 28, 2021

webinar finished

PART II

CONTROVERSIAL
AND MISSING ISSUES
OF RECENT HYPERTENSION
GUIDELINES

May 26, 2021

webinar finished

17.00 #

Introduction

E. Agabiti Rosei (Brescia, Italy), R. Kreutz (Berlin, Germany)

E. Agabiti Rosei (Brescia, Italy), R. Kreutz (Berlin, Germany)

17.05 #

Out of office BP measurement and role of new devices

G. Mancia (Milan, Italy)

G. Mancia (Milan, Italy)

17.20 #

Old and new CV risk factors for the assessment of global risk

G. Grassi (Milan, Italy)

G. Grassi (Milan, Italy)

17.35 #

Essentials in the workup of secondary hypertension

A. Januszewicz (Warsaw, Poland)

A. Januszewicz (Warsaw, Poland)

17.50 #

Thresholds and targets of treatment

J. Redon (Valencia, Spain)

J. Redon (Valencia, Spain)

18.05 #

Combination treatment

A. Coca (Barcelona, Spain)

A. Coca (Barcelona, Spain)

17.00 #

Introduction

A. Januszewicz (Warsaw, Poland), G. Mancia (Milan, Italy)

A. Januszewicz (Warsaw, Poland), G. Mancia (Milan, Italy)

17.05 #

Adherence to treatment

M. Burnier (Lausanne, Switzerland)

M. Burnier (Lausanne, Switzerland)

17.20 #

Covid-19 and antihypertensive treatment

R. Kreutz (Berlin, Germany)

R. Kreutz (Berlin, Germany)

17.35 #

Treatment of concomitant cardiometabolic risk factors and HMOD

E. Agabiti Rosei (Brescia, Italy)

E. Agabiti Rosei (Brescia, Italy)

17.50 #

Treatment with antiplatelets and anticoagulants

A.J. Manolis (Athens, Greece)

A.J. Manolis (Athens, Greece)

18.05 #

Device based treatment

C. Tsioufis (Athens, Greece)

C. Tsioufis (Athens, Greece)

#webinars

CONTACT INFO

ORGANISING SECRETARIAT
AIM Group International – Rome Office
Via Flaminia, 1068 – 00189 Rome, Italy
ph +39-06 330531 – fax +39-0623325630

info

Supported

#

Supported by an unrestricted educational grant by
Menarini Group

menarini

#

ORGANISING SECRETARIAT

ORGANISING

logoAIM